OBJECTIVE - Interleukin-1 receptor antagonist (IL-IRa), a natural inhibitor of interleukin-lβ, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-IRa are associated with incident type 2 diabetes during more than 10 years of follow-up. RESEARCH DESIGN AND METHODS - We measured serum IL-IRa concentrations in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic control subjects) within the Whitehall II cohort (U.K.). RESULTS - IL-IRa concentrations were higher in case subjects (P = 0.0006) and associated with incident type 2 diabetes (odds ratio fora 1-SD increase of IL-IRa 1.48 [95% CI 1.21-1.80]). This association remained significant after adjustment for multiple potential confounders but was attenuated by adjusting for 2-h glucose. CONCLUSIONS - Our findings indicate that individuals who will develop type 2 diabetes are characterized by a complex immune activation that also includes upregulation of the anti-inflammatory cytokine IL-IRa.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialised Nursing